Pfizer Inc. (PFE) ELREXFIO Meets Phase 3 PFS Goal vs SOC in RRMM

Pfizer (PFE) reported positive Phase 3 trial results for ELREXFIO in relapsed or refractory multiple myeloma, meeting its primary endpoint of progression-free survival. The study showed significant risk reduction compared to existing treatments. Pfizer also announced FDA approval for Talzenna in combination with Xtandi for metastatic hormone-sensitive prostate cancer with HRR gene mutations. PFE stock is down slightly in pre-market trading.

Pfizer's ELREXFIO met primary endpoint in Phase 3 trial for multiple myeloma, showing 68% 18-month PFS. The study involved 523 patients. No new safety concerns were found. Pfizer plans regulatory submissions and future data presentations. PFE shares were down 0.34% in pre-market trading.

Pfizer reported positive Phase 3 trial results for ELREXFIO in multiple myeloma, showing 68% of patients alive without disease progression at 18 months. The trial compared ELREXFIO to standard regimens, with Pfizer planning global regulatory submissions. ELREXFIO is already approved in the U.S. for certain patients, and Pfizer is exploring earlier treatment uses.

The FDA expanded Pfizer's Talzenna-Xtandi approval for earlier prostate cancer treatment. Based on the TALAPRO-3 study, the combo reduced progression/death risk by 52%. It now treats metastatic hormone-sensitive prostate cancer with HRR gene mutations. Pfizer aims to address unmet needs in this patient population.

Pfizer (PFE) reported that its Phase 3 study of ELREXFIO (elranatamab) met its primary endpoint, showing a significant reduction in disease progression or death in relapsed or refractory multiple myeloma patients. The study involved 523 adults across 26 countries. Pfizer plans to submit the data to global health authorities. ELREXFIO is already approved in over 35 countries for similar indications.

Pfizer's Phase 3 MagnetisMM-32 trial of ELREXFIO (elranatamab) met its primary endpoint, showing a statistically significant reduction in disease progression or death for multiple myeloma patients. Over 75% of patients showed no progression or death at analysis. Pfizer plans to submit these data to global health authorities. ELREXFIO demonstrated a favorable safety profile, with no new safety signals identified.